News articles about Foundation Medicine (NASDAQ:FMI) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Foundation Medicine earned a news impact score of 0.11 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.0014215313704 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news headlines that may have impacted Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

Shares of Foundation Medicine stock opened at $82.60 on Thursday. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.90. The firm has a market capitalization of $2,980.05, a PE ratio of -18.36 and a beta of -0.21. Foundation Medicine has a fifty-two week low of $29.90 and a fifty-two week high of $87.10.

Foundation Medicine (NASDAQ:FMI) last announced its quarterly earnings data on Wednesday, March 7th. The company reported ($1.05) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.08). The firm had revenue of $48.90 million during the quarter, compared to the consensus estimate of $48.69 million. Foundation Medicine had a negative net margin of 105.60% and a negative return on equity of 207.73%. The firm’s quarterly revenue was up 69.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.02) earnings per share. equities analysts anticipate that Foundation Medicine will post -4.22 EPS for the current year.

Several research analysts recently commented on the company. BidaskClub cut Foundation Medicine from a “buy” rating to a “hold” rating in a research note on Thursday, March 15th. Wells Fargo reissued a “market perform” rating and issued a $80.00 price objective (up from $67.00) on shares of Foundation Medicine in a report on Thursday, March 8th. Finally, Zacks Investment Research raised Foundation Medicine from a “sell” rating to a “hold” rating in a report on Thursday, February 8th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $69.60.

In other news, CEO Troy Cox sold 26,713 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $70.13, for a total transaction of $1,873,382.69. Following the completion of the transaction, the chief executive officer now directly owns 224,345 shares of the company’s stock, valued at $15,733,314.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Robert W. Hesslein sold 1,864 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $64.00, for a total value of $119,296.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 294,952 shares of company stock valued at $20,147,318. 2.70% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Foundation Medicine (FMI) Stock Price” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at

Foundation Medicine Company Profile

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with's FREE daily email newsletter.